Peled, N. Et Al. 2021. GLASS: Global Lorlatinib for ALK(+) and ROS1(+) Retrospective Study: Real World Data of 123 NSCLC Patients. JOURNAL OF THORACIC ONCOLOGY , vol.16, no.3 .

Peled, N., Gillis, R., Kilickap, S., Froesch, P., Orlov, S., Filippova, E., ... Demirci, U.(2021). GLASS: Global Lorlatinib for ALK(+) and ROS1(+) Retrospective Study: Real World Data of 123 NSCLC Patients. JOURNAL OF THORACIC ONCOLOGY , vol.16, no.3.

Peled, N. Et Al. "GLASS: Global Lorlatinib for ALK(+) and ROS1(+) Retrospective Study: Real World Data of 123 NSCLC Patients," JOURNAL OF THORACIC ONCOLOGY , vol.16, no.3, 2021

Peled, N. Et Al. "GLASS: Global Lorlatinib for ALK(+) and ROS1(+) Retrospective Study: Real World Data of 123 NSCLC Patients." JOURNAL OF THORACIC ONCOLOGY , vol.16, no.3, 2021

Peled, N. Et Al. (2021) . "GLASS: Global Lorlatinib for ALK(+) and ROS1(+) Retrospective Study: Real World Data of 123 NSCLC Patients." JOURNAL OF THORACIC ONCOLOGY , vol.16, no.3.

@article{article, author={N. Peled Et Al. }, title={GLASS: Global Lorlatinib for ALK(+) and ROS1(+) Retrospective Study: Real World Data of 123 NSCLC Patients}, journal={JOURNAL OF THORACIC ONCOLOGY}, year=2021}